Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
Allogeneic stem cell transplantation (SCT) from an HLA-haploidentical relative provides a potentially curative treatment option for hematologic malignancies patients who lack a suitably HLA-matched donor. The greatest challenge to performing HLA-haploidentical SCT has been high rates of graft failur...
Main Authors: | Munchel, Ashley, Kesserwan, Chimen, Symons, Heather J., Luznik, Leo, Kasamon, Yvette L., Jones, Richard J., Fuchs, Ephraim J. |
---|---|
Format: | Online |
Language: | English |
Published: |
PAGEPress Publications
2011
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3206539/ |
Similar Items
-
Comparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched Transplantation
by: McCurdy, Shannon R., et al.
Published: (2015) -
How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?
by: Chang, Ying-Jun, et al.
Published: (2016) -
Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case Report
by: Liu, Wei-Hsin, et al.
Published: (2015) -
Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses after Haploidentical Bone Marrow Transplantation with Posttransplantation Cyclophosphamide
by: McCurdy, Shannon R., et al.
Published: (2016) -
Overview of the progress on haploidentical hematopoietic transplantation
by: Farhadfar, Nosha, et al.
Published: (2016)